This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Keeps Their Buy Rating on Cardinal Health (CAH)

Tipranks - Tipranks - Thu Jun 11, 4:28AM CDT

Barclays analyst Glen Santangelo maintained a Buy rating on Cardinal Health today and set a price target of $258.00.

Introducing TipRanks MCP for Agents

According to TipRanks, Santangelo is a 4-star analyst with an average return of 3.7% and a 52.43% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Cencora, Medline, and Viatris.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cardinal Health with a $246.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Cardinal Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $60.94 billion and a net profit of $399 million. In comparison, last year the company earned a revenue of $54.88 billion and had a net profit of $506 million

Read More on CAH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).